NTHI Phase 2 readout: a negative outcome, -20.5%

On August 12, 2026, NEO212 Oral Capsule — NEONC TECHNOLOGIES HOLDINGS, INC. (Diffuse Astrocytoma, IDH-Mutant) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -20.5% in the window around the event. It had already run -19.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.